MedicalDevice Licensing.com
Pharmalicensing.com
Latest: Watch here for details of new products and services.
RSS Feeds
Advanced search

Login  Register

About Us
Pharmalicensing - Partnering solutions for the life sciences
 
Our Products
Overview
Partnering Search
Company Profiling
Deal Negotiation
PL Intelligence
Reports
Comparison
 
PL Intelligence
Overview
Industry news
Deals review
Press releases
Articles
 
Case Studies
See what others think about our service
 
Newsletter
Partnering update
Key reports
Subscribe
 
Quick Links
Profile now
Register now
Profiled companies
Featured events
Industry news
PR Newswire
Jobs
 
Contact Pharmalicensing
Send an email
Call us: +44 1904 520460
Request a callback
 
RSS Feeds
Keep up to date

Pharmalicensing
is a division of
UTEK Europe Ltd
UTEK Corporation
Out-licensing

Radiotracers for Imaging P-glycoprotein Transporter Function

National Institutes of Health (NIH)
This class of radiotracer is designed to restrict the formation of radiometabolites that would obstruct the measurement of P-gp function at the blood-brain barrier or at tumors.

Full description

This invention offers technology to help treat certain brain diseases, such as Alzheimer’s disease and Parkinson’s, and may lead to more effective and personalized treatments.  P-glycoprotein transporter (P-gp) acts as a pump at the blood-brain barrier to exclude a wide range of xenobiotics (e.g., toxins, drugs, etc.) from the brain and is also expressed in a tumor in response to exposure to established/prospective chemotherapeutics (a phenomenon known as multidrug resistance; MDR).  The instant invention relates to compounds that are avid substrates for P-gp, and their preparation and use as radiotracers for imaging P-gp function in vitro and in vivo.

 

Applications: 
These radiotracers have potential application for investigating the function of P-gp at the blood-brain barrier for human subjects and patients in relation to neuropsychiatric disorders and in cancer.  Their application may lead to a better general understanding of the role of P-gp in the unfolding of certain brain diseases (e.g. Alzheimer’s disease, Parkinson’s disease), and ultimately to more effective and personalized treatment. Likewise, these radiotracers may be applied in oncology to help understand MDR and its clinical manifestation, and to help seek out cancer therapies that avoid MDR.

 

Advantages: 
This class of radiotracer, typified by the described [11C]dLop, is designed to restrict the formation of radiometabolites that would obstruct the measurement of P-gp function at the blood-brain barrier or at tumors.  In this sense these radiotracers are vastly superior to progenitors (e.g. [11C]verapamil, [11C]loperamide), which can only give qualitative not quantitative information.

 

Development Status: 
Radiotracer studies in human subjects are in progress.  Longer-lived versions of the radiotracers are in development.

 

Market: 
These radiotracers may be of interest to those wishing to market and/or apply such radiotracers in the medical imaging field.

 

Publications:

  1. SS Zoghbi, JS Liow, F Yasuno, J Hong, E Tuan, N Lazarova, RL Gladding, VW Pike, RB Innis. 11C-Loperamide and its N-desmethyl radiometabolite are avid substrates for brain P-glycoprotein efflux. J Nucl Med. 2008 Apr;49(4):649-656.  [PubMed abs]
  2. N Lazarova, SS Zoghbi, J Hong, N Seneca, E Tuan, RL Gladding, JS Liow, A Taku, RB Innis, VW Pike. Synthesis and evaluation of [N-methyl-11C]N-desmethyl-loperamide as a new and improved PET radiotracer for imaging P-gp function. J Med Chem. 2008 Oct 9;51(19):6034-6043.  [PubMed abs]
  3. JS Liow, W Kreisl, SS Zoghbi, N Lazarova, N Seneca, RL Gladding, A Taku, P Herscovitch, VW Pike, RB Innis.P-glycoprotein function at the blood-brain barrier imaged using 11C-N-desmethyl-loperamide in monkeys. J Nucl Med. 2009 Jan;50(1):108-115.  [PubMed abs]

 

 

 

Patent information

U.S. Patent Application No. 12/112,994 filed 30 Apr 2008 (HHS Reference No. E-318-2007/0-US-01)

 

Inventors: 
Victor W. Pike, Robert B. Innis, Sami S. Zoghbi, Neva Lazarova (NIMH)

 

Type of business relationship sought

Licensees Sought: 
Available for licensing.

 

Collaborative Research Opportunity: 
The National Institute of Mental Health Molecular Imaging Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize radiotracers for imaging P-gp function.  Please contact Victor Pike at pikev@mail.nih.gov for more information.

 

Clients in focus...

Get the Flash Player to see this rotator.

Partnering and licensing intelligence in life sciences industry
Labtec Pharma
Press releases: Pharmalicensing current industry press releases.

© Copyright 1995-2009 Pharmalicensing, a division of UTEK Europe Ltd UTEK Corporation All rights reserved. Terms and Conditions | Contact us